Drug intelligence / Profile preview

INT-210

Development stage: Phase 2
Lead developer: Yikun Xingjian Biomedical
Modality: Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
Administration: Subcutaneous

Overview

INT-210 is an investigational recombinant humanized interleukin-2 (IL-2) mutein-Fc fusion protein developed by Innostellar Biotherapeutics (Shanghai) Co., Ltd. for the treatment of ulcerative colitis. It is engineered to selectively activate and expand regulatory T cells (Tregs) by favoring binding to the high-affinity trimeric IL-2 receptor complex (CD25/CD122/CD132). By promoting Treg-mediated immune tolerance while minimizing the activation of pro-inflammatory effector T cells and natural killer (NK) cells, INT-210 aims to restore immune homeostasis in patients with autoimmune and inflammatory conditions. The drug is currently in Phase 1 clinical development in China following IND approval.

Targets

IL-2R (Interleukin-2/interleukin-15 receptor complex)

Beyond the preview

Go deeper on INT-210.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on INT-210.

Explore the full profile